| Active Not Recruiting | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 5 Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | 2017-06-26 |
| Terminated | Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (M PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome | Phase 1 / Phase 2 | 2017-05-16 |
| Terminated | Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With Cancer, Solid Tumors | Phase 1 | 2016-06-26 |
| Completed | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor T Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma | — | 2016-06-06 |
| Terminated | Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole Solid Tumors, Ovarian Cancer, Endometrial Cancer | Phase 1 | 2015-06-09 |
| Completed | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Solid Tumor, Malignant Lymphoma, Tumor | Phase 1 | 2011-11-01 |
| Completed | Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Sma Metastatic Non-Small Cell Lung Cancer | Phase 2 | 2011-07-01 |
| Completed | Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutat Solid Tumor | Phase 1 | 2010-10-01 |
| Completed | An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols Advanced Solid Tumors | Phase 1 / Phase 2 | 2010-08-31 |
| Completed | Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2009-09-01 |
| Completed | Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior System Unresectable Hepatocellular Carcinoma | Phase 2 | 2009-09-01 |
| Completed | Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies | Phase 1 | 2009-08-01 |
| Completed | Dose Escalation Study of ARQ 197 in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2009-03-01 |
| Completed | Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC) Cirrhosis, Hepatocellular Carcinoma | Phase 1 | 2009-01-01 |
| Completed | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients Wi Non Small Cell Lung Cancer | Phase 2 | 2008-09-01 |
| Completed | Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers Healthy | Phase 1 | 2008-04-01 |
| Completed | A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Meta Healthy | Phase 1 | 2008-03-01 |
| Completed | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors Cancer | Phase 1 | 2008-02-01 |
| Completed | A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Pancreatic Neoplasms | Phase 2 | 2007-11-01 |
| Completed | Phase 2 Study in Patients With MiT Tumors Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS), Clear Cell Sarcoma (CCS) | Phase 2 | 2007-10-01 |
| Completed | An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2007-08-01 |
| Completed | A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors Cancer, Advanced Solid Tumors | Phase 1 | 2007-04-01 |
| Completed | An Extension Study for Patients Previously Treated With ARQ 501 Cancer | Phase 1 / Phase 2 | 2006-12-01 |
| Terminated | A Study of ARQ 171 in Patients With Advanced Solid Tumors Cancer | Phase 1 | 2006-11-01 |
| Completed | A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck Head and Neck Neoplasms, Carcinoma, Squamous Cell | Phase 2 | 2006-07-01 |
| Completed | Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma Cancer | Phase 2 | 2006-02-01 |
| Completed | ARQ 197 in Subjects With Metastatic Solid Tumors Cancer, Tumor | Phase 1 | 2006-01-01 |
| Completed | ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer Pancreatic Cancer, Adenocarcinoma | Phase 2 | 2005-01-01 |
| Completed | ARQ 501 in Combination With Docetaxel in Patients With Cancer Carcinoma | Phase 1 | 2004-12-01 |
| Completed | ARQ 501 in Subjects With Cancer Cancer | Phase 1 | 2003-09-01 |
| Withdrawn | A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced Gastric Cancer | Phase 2 | — |
| No Longer Available | Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders | — | — |